WO2007125731A1

WO2007125731A1 - Soft contact lens solution, drug-sustained release soft contact lens prepared by using the solution

Info

Publication number: WO2007125731A1
Application number: PCT/JP2007/057431
Authority: WO
Inventors: Yuri Mizutani
Original assignee: Menicon Co., Ltd.
Priority date: 2006-04-28
Filing date: 2007-04-03
Publication date: 2007-11-08
Also published as: JPWO2007125731A1

Abstract

Disclosed is a soft contact lens solution which can alleviate an allergic condition without the need of administering a medicinal agent frequently in the form of an eye drop. Also disclosed is a method for production of the solution. A soft contact lens is contacted with a soft contact lens solution comprising an aqueous medium and polyphenol as an allergen-deactivating component contained in the aqueous medium, so that the allergen-deactivating component can be incorporated into the soft contact lens.

Description

Specification

Soft contact lens solution, drug sustained release soft contact lens obtained using the same, and method for producing the same

Technical field

The present invention relates to a soft contact lens solution, a drug sustained-release soft contact lens obtained using the same, and a method for producing the same, and in particular, polyphenol as an allergen-reducing component or an allergen-inactivating component. The present invention relates to a solution for soft contact lenses containing.

Background art

[0002] Conventionally, in people who wear contact lenses on a daily basis, allergic eye diseases such as allergic conjunctivitis have an incidence S, pollen and other allergens adhere to the contact lens, By staying on top, it is believed that it will be higher than those who do not wear contact lenses on a daily basis.

[0003] By the way, in recent years, polyphenols have been known to have an allergen reducing effect or an allergen deactivating effect on allergens in the environment such as pollen, house dust, mites, fungi, and pet hair. I'm going.

[0004] As a technique using the allergen deactivation effect of polyphenol, for example, Patent Document 1 specifies tannic acid, which is a kind of polyphenol, in order to remove allergens such as environmental power mites. It has been clarified that compositions containing these solvents are used for walls, floors, clothing, etc. in the form of liquids, sprays, aerosols and the like. Patent Document 2 discloses an allergen remover containing as an active ingredient at least one component selected from the group consisting of organic solvents, polyphenols such as tannic acid, hydroxyapatite, and cationic surfactants, and The allergen remover is sprayed into the space in the form of fine particles, directly sprayed and applied to allergen deposits, held alone in the container, and collected by passing air containing the allergen. A method for removing allergens has been clarified. Further, Patent Document 3 discloses a wiping sheet for tatami mats using an aromatic hydride compound such as tannic acid or catechin as an allergen deactivating component. ing.

[0005] However, as in the above-mentioned Patent Documents 1 to 3, etc., a conventional drug using the allergen deactivation effect of polyphenol is obtained by impregnating a powerful drug into cloth or paper. It can be used to wipe off allergens, or it can be used by spraying power or chemicals on clothes etc. with a spray. I got it.

[0006] On the other hand, as an antiallergic drug for reducing or alleviating such allergic symptoms, for example, Patent Document 4 discloses that tranilast is applicable to eyes wearing contact lenses. Anti-allergic drug power has been clarified.

[0007] However, anti-allergic drugs such as force and karanilast are generally highly irritating (scratching to the eyes), and most of them require instillation about 4 to 6 times a day. Yes, it was very troublesome with many eye drops. In addition, such antiallergic drugs are those in which powerful drugs are absorbed into the body and exert their actions, so their effects differ depending on the person, and there are also problems such as side effects Met.

Patent Document 1: Japanese Patent Application Laid-Open No. 61-44821

Patent Document 2: Japanese Patent Laid-Open No. 2000-264837

Patent Document 3: Japanese Patent Laid-Open No. 2003-79554

Patent Document 4: Japanese Unexamined Patent Publication No. 2003-81840

Disclosure of the invention

Problems to be solved by the invention

[0009] Here, the present invention has been made against the background of harsh circumstances, and the problem to be solved is to provide a solution for soft contact lenses with less eye irritation. There is. Another solution is to provide a method for producing soft contact lenses that can reduce allergic symptoms without frequent instillation of drugs.

Means for solving the problem

[0010] And, as a result of repeated intensive studies to solve such a problem, the present inventors, as a result of using polyphenol as an allergen deactivating component, does not irritate the eyes, It was found that a solution for soft contact lenses containing an allergen-inactivating component can be obtained that does not penetrate into the eyes. In addition, by appropriately selecting a soft contact lens and incorporating the allergen deactivating component into the powerful contact lens, it is possible to advantageously obtain a soft contact lens that gradually releases the powerful, allergen deactivating component. I found out that it came out.

[0011] Accordingly, the present invention has been completed on the basis of strong knowledge, and in order to solve the problems described above or the problems grasped from the entire description of the specification, various kinds of problems as listed below can be obtained. In the embodiments, the embodiments can be preferably implemented, but the embodiments described below can be adopted in any combination. Note that aspects or technical features of the present invention are not limited to those described below, and the description of the entire specification can be recognized based on the inventive idea disclosed therein. Should be understood.

[0012] (1) A solution for soft contact lenses, comprising polyphenol as an allergen deactivating component in an aqueous medium.

[0013] (2) The solution for soft contact lenses according to the aspect (1), which is the polyphenol S, catechins, or tannic acid.

[0014] (3) The soft contact lens solution according to the above aspect (1) or (2), wherein the polyphenol content power is 0.001 to 10%.

[0015] (4) The soft contact lens force The soft contact lens solution according to any one of the above aspects (1) to (3), which is an ionic soft contact lens.

[0016] (5) The soft contact lens solution according to any one of the above aspects (1) to (4), which is used as a multipurpose solution, a preservation solution, or a distribution preservation solution.

(6) A method for producing a soft contact lens capable of sustained drug release,

a) preparing an aqueous solution containing polyphenol as an allergen deactivating component; and b) bringing a soft contact lens into contact with the aqueous solution and incorporating the allergen deactivating component into the soft contact lens. , A manufacturing method comprising:

[0018] (7) The method for producing a soft contact lens capable of sustained drug release according to the above aspect (6), wherein the polyphenola S, catechins or tannic acid is used.

[0019] (8) The method for producing a soft contact lens capable of sustained drug release as described in the above aspect (6) or (7), wherein the polyphenol content is 0.001 to 10%.

[0020] (9) The soft contact lens force of the soft contact lens capable of sustained drug release according to any one of the above aspects (6) to (8), wherein the soft contact lens force is an ionic soft contact lens. Production method.

(10) Polyphenol as an allergen deactivating component is impregnated in the soft contact lens produced by the production method according to any one of the above aspects (6) to (9). A drug sustained-release soft contact lens characterized by

The invention's effect

Therefore, according to the soft contact lens solution according to the present invention as described above, the use of polyphenol as an allergen deactivating component makes it possible to stimulate the eye such as the drug sees the eye when instilled. Therefore, it is possible to advantageously obtain a soft contact lens solution with a low content.

[0023] In addition, by selecting a soft contact lens as the contact lens to be applied and incorporating the allergen deactivating component into the powerful soft contact lens, the allergen deactivating component is gradually added to the eye. Since it can be continuously released, allergic symptoms can be advantageously reduced with a small number of instillations without frequent instillation of drugs.

BEST MODE FOR CARRYING OUT THE INVENTION

By the way, the soft contact lens solution according to the present invention contains polyphenol as an allergen-reducing component or allergen-inactivating component in an aqueous medium. As a polyphenol used there, Any of those conventionally known can be used. For example, flavonoid polyphenols include flavones, flavonols, isoflavones, flavans, flavanols, flavanones, flavonols, chalcones. , Anthocyanidins, phenylcarboxylic acid polyphenols, etc. It can be illustrated. Of these, tannic acid power S, which is a kind of catechins and phenylcarboxylic acid-type polyphenols, among flavanols, which is a kind of flavonoid-type polyphenols, is particularly preferably used.

[0025] Further, as the catechins pointed out above, more specifically, catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate and methylated derivatives thereof, tea extract (including tea tea) ) In addition, as a plant extract component other than tea, it is possible to list grapes (fruits, leaves, trees), bamboo, bear buds, perilla, roses, gardenia fruits, yew, aloe, rosemary, etc. Needless to say, it is not limited in any way. These compounds can be used alone or in combination of two or more.

[0026] By using polyphenol as described above as an allergen deactivating component, when allergen deactivating component is instilled, the allergens such as pollen on the lens are advantageously reduced. It can be inactivated, or can be made into a contact lens solution that can advantageously suppress irritation to the eye, such as when the medicine is instilled into the eye. Powerful polyphenols have the advantage that they are relatively easy to obtain and are excellent in safety and stability.

[0027] Here, the strong polyphenol is a force that can be appropriately used in an amount effective for deactivating allergens. Generally, it is preferable that the content is 0.001 to 10% on a weight basis. Is used at a content of 0.1-5%. This is because if the content is too low, the allergen deactivation effect due to the inclusion of polyphenols may not be sufficiently exerted, and if the content exceeds the above range, polyphenols may be used. This is because when catechin is used, there is a possibility that problems such as coloring may occur in the lens that is brought into contact with the solution for the soft contact lens.

[0028] The contact lens solution according to the present invention is prepared by adding and incorporating the above-described components into an appropriate aqueous medium in the same manner as in the prior art. In addition to water itself such as tap water, purified water, and distilled water, the aqueous medium used at that time is highly water-safe and ophthalmic as long as the solution is mainly water. Can be used as long as it is sufficiently acceptable to is there.

[0029] Further, in the present invention, as an allergen deactivating component as described above, a solution that is contained in a polyphenol-based aqueous medium is used as a soft contact lens solution. The soft contact lenses to which such a solution is applied are various known soft contact lenses. For example, examples of non-ionic soft contact lenses include soft contact lenses such as butyl acetate and DMAA. Examples of the ionic soft contact lens include HEMA type, N-VP type, MAA type and the like into which an ionic group such as a carboxyl group is introduced.

[0030] In particular, among these soft contact lenses, it is advantageous to be an ionic soft contact lens. Examples of such ionic soft contact lenses include those described above, for example, HEMA (hydroxylethyl methacrylate), N_VP (N-vinyl-1-pyrrolidone), and MAA (methacrylic acid). Can be mentioned. Furthermore, among them, the ionic high water content soft contact lens force having a water content of 50% or more is advantageously targeted.

[0031] Thus, by using a solution containing an allergen deactivating component as a solution for a soft contact lens, when such allergen deactivating component comes into contact with the lens, Therefore, the incorporated allergen-inactivating component is released little by little on the eye continuously over a long period of time, so that allergen is newly added to the lens. Even if it adheres, since it is not necessary to instill a new allergen-inactivating component, allergic symptoms can be advantageously reduced or alleviated with a small number of instillations.

[0032] Further, in the present invention, an ionic soft contact lens is applied as a powerful soft contact lens, whereby an allergen-inactivating component-containing solution force S ionic soft contact lens when in contact with the ionic soft contact lens The effects of color change and size change due to polyphenols (especially catechins) can be advantageously avoided. The reason for this is still not clear enough, but catechin (polyphenol) is slightly soluble in water, but it is basically a highly hydrophobic substance, so in the case of non-ionic soft contact lenses. , Non-ionic lens and catechin (polyphenol) interact hydrophobicly This is considered to be because catechin (polyphenol) aggregates on the lens, and coloring of the lens and a change in size are caused.

[0033] In addition to the above-described components, the soft contact lens solution according to the present invention, in addition to the above-described components, if necessary, various additive components conventionally used in contact lens solutions, For example, one or more of a thickening agent, a pH buffering agent, a cleansing agent, a refreshing agent, a surfactant, an osmotic pressure adjusting agent, a vasoconstrictor, vitamins, an anti-inflammatory agent and a flavoring agent. Even if two or more kinds are appropriately selected and contained in a normal content ratio, there is no problem. However, as such additive components (additives), those that are highly safe to the living body and that are ophthalmically acceptable and that do not affect the shape and physical properties of the contact lens are advantageously selected. The Rukoto.

[0034] It should be noted that the soft contact lens solution in the present invention is a force that can be applied to the soft contact lens in various conventionally known embodiments. Generally, ophthalmic solutions for eyes wearing a soft contour lens. In addition, it is also used as a mounting solution, an eyewash solution, a multi-purpose solution, a preservative solution or a distribution preservative solution, and the soft contact lens is soaked in these liquid agents. The effect of can be produced. Here, the multi-purpose solution means a solution that can perform at least two or more of cleaning, rinsing, disinfection, and storage of contact lenses in one solution. Further, by using the soft contact lens solution of the present invention as a distribution preservation solution for a disposable contact lens, a disposable soft contact lens capable of sustained release of a clean drug can be easily obtained. Thus, the effects of the present invention can be advantageously achieved.

In the present invention, an aqueous liquid preparation containing polyphenol as an allergen deactivating component is prepared in order to produce a soft contact lens capable of sustained drug release using the soft contact lens solution described above. A manufacturing method including a step and a step of bringing a soft contact lens into contact with a force and a liquid aqueous solution and incorporating an allergen deactivating component into the forceful soft contact lens is adopted.

[0036] Here, in the step of incorporating the allergen-inactivating component into the soft contact lens, the soft contact lens force is immersed in the aqueous liquid agent or the aqueous liquid agent is adhered. The force that can be brought into contact with an aqueous solution by tightening

Advantageously, it takes about 30 minutes to 16 hours. If the time is too short, there is a risk that the allergen-inactive component uptake amount of the soft contoured external lens capable of sustained drug release produced in this way may not be sufficient. There is a possibility that the effect cannot be enjoyed advantageously. If the time is longer than the above-mentioned time, the amount of allergen deactivating components taken into the lens reaches saturation, and there is a risk that the effect of soaking for longer than this time cannot be obtained.

[0037] Further, for the same reason as described above, force techkins or tannic acid is advantageously used as the force or karyopolyphenol, and the content of force or kraft polyphenol is generally 0. 001-10%, and in addition, as a soft contact lens that works, an ion soft contact lens is advantageously targeted.

[0038] As described above, the drug can be gradually released by bringing the soft contact lens into contact with an aqueous solution containing polyphenol as an allergen deactivating component so that the allergen deactivating component is incorporated into the strong soft contact lens. This makes it possible to advantageously obtain a soft contact lens.

[0039] A soft contact lens produced by the above-described method and impregnated with polyphenol as an allergen deactivating component functions advantageously as a drug sustained-release soft contact lens. To do.

[0040] That is, there is a soft contact lens that can advantageously suppress irritation to the eye, such as when it is instilled, since polyphenol is used as an allergen deactivating component. The solution for use can be advantageously obtained. In addition, by using a drug sustained-release soft contact lens in which an allergen deactivating component is impregnated in the soft contact lens, when a powerful lens is attached to the eye, it is taken into the lens on the eye. In addition, the allergen deactivating component can be released gradually, in other words, the force, the allergen deactivating component can be released little by little continuously.

[0041] Therefore, the allergen deactivating component is released from the strong soft contact lens continuously on the eye for a long time, so that the allergen reducing effect or the deactivating effect is advantageously enjoyed for a long time. This makes it possible to reduce the need for frequent instillation of drugs. It is possible to reduce or alleviate allergic symptoms advantageously with no instillation.

Example

[0042] The following are some examples of the present invention, and the power to further clarify the present invention. The present invention is not limited by the description of such examples. It goes without saying that it is not something to receive. In addition to the following examples, various changes, modifications, improvements, and the like can be added to the present invention based on the knowledge of those skilled in the art without departing from the spirit of the present invention. Should be understood.

[0043] First, the efficacy against the cedar pollen antigen and the efficacy against the cedar pollen of the allergen-inactivating component used in the present invention were evaluated by ELISA (Examples 1 to 30, Comparative Examples:! To 5), The results are shown in Tables 1 to 9 below. Furthermore, the results evaluated by the flow cytometry (FCM) method (Examples 31 to 35, Comparative Examples 6 to 11) are shown in Table 10 below. Note that the evaluation was performed when the fluorescence emission rate (activity rate) was 0% or more and 45% or less, and X was given when X was over 45%.

[0044] Example 1

The antibody for solid phase against the cedar pollen antigen Cryj l is immobilized on a 96-well plate, and there are epicatechin (EC): about 7%, epicatechin gallate (ECG): about 12%, and epigallocatechin (EGC): about 25%, Epigalocatechin gallate (EGCG): Phosphate-Buffered Salts solution containing 0.1% Lw / v% urine serum albumin (hereinafter 0.1% BSA-containing PBS solution) of the remaining catechin mixture (hereinafter the same) And a mixture of 0.1% BSA-containing PBS solution of cedar pollen antigen Cryj l, followed by addition of peroxidase-labeled anti-Cryj l antibody as a fluorescently labeled antibody, and absorbance at 490 nm Was measured, and the fluorescence emission rate was determined. Table 1 below shows the concentrations of reagents used in the catechin mixture and the ELISA test, and the fluorescence emission efficiency obtained.

[0045] Example 2, 3—

Except that the concentration of the catechin mixture was changed to the concentration shown in Table 1 below, the ELISA test was conducted in the same manner as in Example 1 to obtain the fluorescence emission rate. The results are also shown in Table 1 below. [0046] Comparative Example 1

Immobilize antibody for solid phase against cedar pollen antigen Cryj l in 96-well plate, add 0.1% BSA-containing PBS solution, then add peroxidase-labeled anti-Cryj l antibody as fluorescently labeled antibody Then, the absorbance at 490 nm was measured to determine the fluorescence emission rate. Table 1 below shows the concentrations of the catechin mixture and the reagents used in the ELISA test and the fluorescence emission efficiency obtained.

[0047] Comparative Example 2—

Immobilize antibody for solid phase against cedar pollen antigen Cryj l in 96-well plate, add 0.1% BSA-containing PBS solution of cedar pollen antigen Cryj l to it, and then peroxidase label as fluorescently labeled antibody Anti-Cryjl antibody was added, and the absorbance at 490 nm was measured to determine the fluorescence emission rate. Table 1 below shows the concentrations of the reagents used in the catechin mixture and the ELISA test, and the fluorescence emission efficiency obtained.

[0048] Example 4, 5—

An ELISA test was carried out in the same manner as in Example 1 except that the catechin mixture concentration and the cedar pollen antigen Cryjl concentration were those shown in Table 1, and the fluorescence emission rate was determined. The results are also shown in Table 1 below.

[0049] Comparative Example 3—

An ELISA test was carried out in the same manner as in Comparative Example 2 except that the cedar pollen antigen Cryjl concentration was changed to the concentration shown in Table 1, and the fluorescence emission rate was determined. The results are also shown in Table 1 below.

[0050] [Table 1]

Liquid mixture Antibody for solid phase Antigen (Cryj l) H RP—Anti-Cryj l Fluorescence emission rate

Inhibition Concentration (taCryj l Degree ίΛίί · Concentration (Activity)

(w / v%) (χ / g / mL) ngz m) (ng / m effect)

(%)

Example 1 1 10 2 500 0 ○ Example 2 0.5 10 2 500 0 ○ Example 3 0.1 10 2 500 45 ○ Comparative Example 1 0 10 0 500 0 X Comparative Example 2 0 10 2 500 100 X Example 4 0.1 10 0.5 500 27 〇 Example 5 0.01 10 0.5 500 40 O Comparative example 3 0 10 0.5 500 100 X

[0051] Example 6—

An ELI SA test was conducted in the same manner as in Example 1 except that tannic acid was used in place of the catechin mixture, and the fluorescence emission rate was determined. Table 2 below shows the concentrations of the reagents used in the tannic acid and ELISA tests, and the fluorescence emission efficiency obtained.

[0052] One Example 7, 8-An ELI SA test was performed in the same manner as in Example 6 except that the tannoic acid concentration was changed to the concentration shown in Table 2 below, and the fluorescence emission rate was determined. The results are also shown in Table 2 below.

[0053] [Table 2]

Example 9

An ELISA test was carried out in the same manner as in Example 2 except that epicarocatechin 3 "-O-methyl (hereinafter abbreviated as EGCG-Me) was used instead of the catechin mixture to determine the fluorescence emission rate. Table 3 below shows the concentrations of the reagents used in the EGCG-Me and ELISA tests, and the fluorescence efficiency obtained. [0055] Example 10—

Except that the concentration of EGCG-Me was changed to the concentration shown in Table 3 below, the ELISA test was conducted in the same manner as in Example 9 to obtain the fluorescence emission rate. The results are also shown in Table 3 below.

[0056] [Table 3]

[0057] One Example 11

An ELISA test was performed to determine the fluorescence emission rate in the same manner as in Example 1, except that epicarocatechin gallate (hereinafter abbreviated as EGCG) was used instead of the catechin mixture. Table 4 below shows the concentrations of the reagents used in the EGCG and ELISA tests and the determined fluorescence emission efficiency.

[0058] Examples 12, 13—

An ELISA test was performed in the same manner as in Example 11 except that the EGCG concentration was changed to the concentration shown in Table 4 below, and the fluorescence emission rate was obtained. The results are also shown in Table 4 below.

[0059] [Table 4]

Example 14

Instead of the catechin mixture, force techin gallate (hereinafter abbreviated as CG) was used in the same manner as in Example 1, and an ELISA test was performed to determine the fluorescence emission rate. CG and ELIS Table 5 below shows the concentration of the reagent used in the A test and the obtained fluorescence emission efficiency.

[0061] Examples 15, 16—

An ELISA test was carried out in the same manner as in Example 14 except that the CG concentration was changed to the concentration shown in Table 5 below, and the fluorescence emission rate was determined. The results are also shown in Table 5 below.

[0062] [Table 5]

[0063] Example 17-

An ELISA test was carried out in the same manner as in Example 1 except that epicatechin gallate (hereinafter abbreviated as ECG) was used in place of the catechin mixture, and the fluorescence emission rate was determined. Table 6 below shows the concentrations of the reagents used in the ECG and ELISA tests, as well as the calculated fluorescence emission efficiency.

[0064] Example 18-

An ELISA test was carried out in the same manner as in Example 17 except that the ECG concentration was changed to the concentration shown in Table 6 below, and the fluorescence emission rate was determined. The results are also shown in Table 6 below.

[0065] [Table 6]

Example 19

An antibody for solid phase against cedar pollen antigen Cryj2 was immobilized on a 96-well plate, After adding a mixed solution of 0.1% BSA-containing PBS solution of the Tekin mixture and 0.1% BSA-containing PBS solution of cedar pollen antigen Cryj2, add peroxidase-labeled anti-Cryj2 antibody as a fluorescently labeled antibody. The absorbance at 490 nm was measured to determine the fluorescence emission rate. Table 7 below shows the concentrations of the catechin mixture and the reagents used in the ELISA test and the fluorescence emission efficiency obtained.

[0067] One Example 20-22—

An ELISA test was carried out in the same manner as in Example 19 except that the concentration of the catechin mixture was changed to the concentration shown in Table 7 below, and the fluorescence emission rate was determined. The results are also shown in Table 7 below.

[0068] One Comparative Example 4

Immobilize a solid phase antibody against the cedar pollen antigen Cryj2 in a 96-well plate, add 0.1% BSA-containing PBS solution, and then add peroxidase-labeled anti-Cryj2 antibody as a fluorescently labeled antibody. The absorbance at 490 nm was measured to determine the fluorescence emission rate. Table 7 below shows the concentrations of the catechin mixture and the reagents used in the ELISA test and the fluorescence emission efficiency obtained.

[0069] Comparative Example 5—

Immobilize a solid phase antibody against cedar pollen antigen Cryj2 in a 96-well plate, add 0.1% BSA-containing PBS solution of cedar pollen antigen Cryj2 to it, and then add peroxidase-labeled anti-fluorescent antibody as a fluorescent-labeled antibody. Cryj 2 antibody was added, and the absorbance at 490 nm was measured to determine the fluorescence emission rate. Table 7 below shows the concentration of the catechin mixture and the reagents used in the ELISA test and the fluorescence emission efficiency obtained.

[0070] [Table 7] Catechin mixture Solid phase antibody Antigen (Cryj2) HRP-anti-Cryj2 Fluorescence emission rate

(Anti-Cryj2) concentration suppression

；辰辰体 ί 辰度 (Activity)

(w / v ° / o) (; U gZmL) kng / mL) Effect

(ng / mL) (%) Example 1 9 1 10 5 250 0 O Example 2 0 0.5 10 5 250 0 0 Example 2 1 0.1 10 5 250 0 o Example 2 2 0.01 10 5 250 3 o Comparative Example 4 0 10 0 250 0 X Comparative Example 5 0 10 5 250 100 X [0071] Example 23-

An ELISA test was conducted to determine the fluorescence emission rate in the same manner as in Example 19 except that epicarocatechin gallate (EGCG) was used instead of the catechin mixture. Table 8 below shows the concentrations of the reagents used in the EGCG and ELISA tests and the obtained fluorescence emission efficiency.

[Example] 24-26-

An ELISA test was performed in the same manner as in Example 23 except that the EGCG concentration was changed to the concentration shown in Table 8 below, and the fluorescence emission rate was determined. The results are also shown in Table 8 below.

[0073] [Table 8]

[0074] Example 27-

An ELISA test was conducted in the same manner as in Example 19 except that tannic acid was used in place of the catechin mixture, and the fluorescence emission rate was determined. Table 9 below shows the concentrations of the tannic acid and the reagents used in the ELISA test and the obtained fluorescence emission efficiency.

[0075] Examples 28-30-

An ELISA test was performed in the same manner as in Example 27 except that the EGCG concentration was changed to the concentration shown in Table 9 below, and the fluorescence emission rate was obtained. The results are also shown in Table 9 below.

[0076] [Table 9] Tannic acid Solid phase antibody Antigen (Cryj2) H P-¾Cryj2 Fluorescence emission rate

Suppression

'Degree of spread (anti-Cryj2) concentration level 1 · Body i level of spread (activity)

(w / v%) (// g / mL) tng / m) (ng / mL) Effect

(%) Example 2 7 1 10 5 250 0 ○ Example 2 8 0.5 10 5 250 0 ○ Example 2 9 0.1 10 5 250 0 0 Example 3 0 0.01 10 5 250 31 ○ Comparative example 4 0 10 0 250 0 X Comparative Example 5 0 10 5 250 100 X

Example 31-After adding a mixture of 0.1% BSA-containing Pollen-Sorting Buffer of catechin mixture and anti-Cryj l antibody to cedar pollen, a fluorescently labeled antibody (FITC-labeled antibody) that recognizes the antibody and Then, a FITC-labeled anti-mouse IgG antibody was added, irradiated with a 488 nm argon laser, the fluorescence intensity at a fluorescence wavelength: 525 nm (excitation wavelength: 495 nm) was measured, and the fluorescence emission rate was determined. Table 10 below shows the concentration of the reagents used in the catechin mixture and the flow cytometry test, and the fluorescence emission efficiency obtained.

[0078] One Example 32—

Except that the concentration of the catechin mixture was changed to the concentration shown in Table 10 below, a flow cytometry test was conducted in the same manner as in Example 31 to obtain the fluorescence emission rate. The results are also shown in Table 10 below.

[0079] Comparative Example 6—

After adding a buffer solution to the cedar pollen, add a FITC-labeled anti-mouse IgG antibody as a fluorescent-labeled antibody that recognizes the antibody (FITC-labeled antibody), irradiate it with an argon laser of 488 nm, and emit a fluorescence wavelength of 525 nm The fluorescence intensity at (excitation wavelength: 495 nm) was measured, and the fluorescence emission rate was determined. Table 10 below shows the concentration of the reagents used in the flow cytometry test and the fluorescence emission efficiency obtained.

Comparative Example 7- After adding anti-Cryj l antibody to cedar pollen, FITC-labeled anti-mouse IgG antibody is added as a fluorescent-labeled antibody that recognizes the antibody (FITC-labeled antibody), and the fluorescence intensity at 525 nm Was measured, and the fluorescence emission rate was determined. Concentration of reagents used for flow cytometry test The obtained fluorescence efficiency is shown in Table 10 below.

[0081] Examples 33, 34, Comparative Examples 8, 9—

A flow cytometry test was carried out in the same manner as in Examples 31 and 32 and Comparative Examples 6 and 7 except that an anti-Cryj 2 antibody was used in place of the anti-Cryj 1 antibody, and the fluorescence emission rate was determined. The results are also shown in Table 10 below.

[0082] Example 35—

A flow cytometry test was carried out in the same manner as in Example 31 except that the concentration of catechin mixture and the amount of cedar pollen were changed to the concentrations shown in Table 10 below, and the fluorescence emission rate was determined. The results are also shown in Table 10 below.

[0083] Comparative Example 10, 11-A flow cytometry test was conducted in the same manner as Comparative Examples 6 and 7 except that the amount of cedar pollen was changed to the concentration shown in Table 10 below. Asked. The results are also shown in Table 10 below.

[Table 10]

As is clear from the results in Tables 1 to 10, in the soft contact lens solution according to the present invention, the polyphenol used as an allergen deactivating component effectively inhibits the cedar pollen antigen cryj l and the cedar pollen allergen. Inactivated, such pollen etc. Even if the allergen adheres to the lens, it can be advantageously deactivated, so that allergic symptoms caused by such allergen can be effectively reduced or mitigated. It becomes.

[0085] Further, a release test of allergen-inactivating components used in the present invention was conducted (Examples 36 to 40), and the results are shown in Table 11 below. Furthermore, the coloring property and size change of the lens by polyphenol as an allergen deactivating component were also examined.

[0086] One Example 36—

After immersing a HEMA ionic high water content soft contact lens having a hydroxyl group (water content: 55%) in an aqueous solution of a catechin mixture having various concentrations shown in Table 11 below for 16 hours, 0.9% by weight The amount of the catechin mixture released by immersion in physiological saline was measured over time. Table 11 below shows the concentration and release rate of the catechin mixture released after 4 hours. In addition, the coloration of the lens and the size change of the lens by the catechin mixture at various concentrations were also confirmed.

[0087] Example 37-

Example 36 except that a DMAA (N, N dimethylacrylamide) non-ionic high water content soft contact lens (water content: 72%) was used instead of the HEMA type ionic high water content soft contact lens. Thus, the amount of catechin mixture released was measured over time. The concentration and release rate of the obtained catechin mixture after 4 hours are also shown in Table 11 below. In addition, the coloration of the lens by the catechin mixture at various concentrations and the size change of the lens were also confirmed.

[0088] Example 38-

The amount of EGCG released was measured over time in the same manner as in Example 36, except that an epigallocatechin gallate (EGCG) aqueous solution was used instead of the aqueous solution of the catechin mixture. The obtained release EGCG concentration and release rate after 4 hours are also shown in Table 11 below. In addition, the colorability of the lens by EGCG at various concentrations and the change in lens size were also confirmed.

[0089] One Example 39—

Instead of HEMA ionic high water content soft contact lenses, DMAA (N, N—dimethyl Chill acrylamide) based nonionic high water content soft contact lenses (water content: ^7, except that there use 2%), in the same manner as in Example 38, the EGCG amount emitted was measured over time. The obtained release EGCG concentration and release rate after 4 hours are also shown in Table 11 below. In addition, the colorability of the lens by EGCG at various concentrations and the change in lens size were also confirmed.

[0090] One Example 40—

EGCG released in the same manner as in Example 38, except that a silicone nano-mouth gel soft contact lens having a silicon component (water content: 24%) was used instead of the HEMA ionic high water content soft contact lens. The amount was measured over time. The obtained release EGCG concentration and release rate after 4 hours are also shown in Table 11 below. We also confirmed the coloration of the lens by EGCG and the size change of the lens at various concentrations.

[0091] [Table 11]

In any of the soft contact lenses apparent from the results in Table 11 above, it was found that the polyphenol was effectively retained and gradually released over time. Compared with non-ionic soft contact lenses, ionic soft contact lenses have a higher polyphenol concentration (release rate) after 4 hours. It has been found that a sustained release of 1 liter takes place over a longer period of time. Further, it was found that when epicarocatechin gallate (EGCG) is used as polyphenol, sustained release over a long period of time is advantageously performed.

[0093] Regarding the colorability of the lens with polyphenol, in the HEMA-based ionic high water content soft contact lens, the power to develop a yellow-green color when the polyphenol concentration is 0.5% or more is highly transparent. Admitted. On the other hand, in the DMAA non-ionic high water content soft contact lens, it was observed that the polyphenol concentration was 0.5% or more and the color turned brown (dark blue).

[0094] Further, regarding the lens size change due to polyphenol, in the HEMA ionic high water content soft contact lens, no lens size change was observed even at a high polyphenol concentration. On the other hand, in the case of DMAA non-ionic high water content soft contact lenses, the lens size decreases when the polyphenol concentration is 0.1% or more, and the lens size decreases by about 20% when the polyphenol concentration is 0.5% or more. Admitted.

Claims

The scope of the claims

[1] A solution for soft contact lenses, comprising polyphenol as an allergen deactivating component in an aqueous medium.

2. The soft contact lens solution according to claim 1, wherein the polyphenol is catechins or tannic acid.

[3] The soft contact lens solution according to [1] or [2], wherein the polyphenol content power is 0.001 to 10%.

[4] The soft contact lens solution according to any one of claims 1 to 3, wherein the soft contact lens force is an ionic soft contact lens.

[5] The soft contact lens solution according to any one of claims 1 to 4, wherein the soft contact lens solution is used as a multipurpose solution, a preservation solution, or a distribution preservation solution.

[6] A method for producing a soft contact lens capable of sustained drug release,

a) preparing an aqueous solution containing polyphenol as an allergen deactivating component; and b) bringing a soft contact lens into contact with the aqueous solution and incorporating the allergen deactivating component into the soft contact lens. ,

A manufacturing method comprising:

[7] The method for producing a soft contact lens capable of sustained drug release according to [6], which is the polyphenolcatechin or tannic acid.

[8] The method for producing a soft contact lens capable of sustained drug release as described in [6] or [7], wherein the polyphenol content power is 0.001 to 10%.

[9] The method for producing a soft contact lens capable of sustained drug release according to any one of [6] to [8], wherein the soft contact lens force is an ionic soft contact lens.

[10] The soft contact lens produced by the production method according to any one of claims 6 to 9 is impregnated with polyphenol as an allergen deactivating component. The drug sustained release soft contact lens.